DPP4Is心血管安全性综述:重点关注阿格列汀

A. Trailokya, A. Zargar, M. Tiwaskar, S. Kale, Amar Shirsat
{"title":"DPP4Is心血管安全性综述:重点关注阿格列汀","authors":"A. Trailokya, A. Zargar, M. Tiwaskar, S. Kale, Amar Shirsat","doi":"10.18231/j.ijpp.2023.013","DOIUrl":null,"url":null,"abstract":"DPP-4 inhibitors are present in the market for almost more than a decade. In Management of T2DM, DPP-4 inhibitors are established therapy option. The precise guidance for the pre- and post-approval and also CV safety of the newer antidiabetic agents was released by the USFDA in 2008. A neutral effect of Pooled safety analyses, as well as retrospective meta-analyses of clinical trials, have consistently demonstrated that DPP-4 inhibitors are not associated with any increase in cardiovascular adverse events, and have even pointed towards a risk reduction. The combination therapy of Alogliptin with other agents like metformin and pioglitazone have been shown to provide better and superior efficacy as compared to individual monotherapy. The hypoglycemic risk is less with Alogliptin. Alogliptin has been shown to be associated with less risk of hepatotoxicity, weight gain, and acute pancreatitis. Alogliptin does not worsen outcomes in patients with a history of heart failure (HF), neither does it increase rate of new hospitalization for heart failure (HF), as per the data from EXAMINE trial.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Commentary on cardiovascular safety of DPP4Is: Focus on Alogliptin\",\"authors\":\"A. Trailokya, A. Zargar, M. Tiwaskar, S. Kale, Amar Shirsat\",\"doi\":\"10.18231/j.ijpp.2023.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"DPP-4 inhibitors are present in the market for almost more than a decade. In Management of T2DM, DPP-4 inhibitors are established therapy option. The precise guidance for the pre- and post-approval and also CV safety of the newer antidiabetic agents was released by the USFDA in 2008. A neutral effect of Pooled safety analyses, as well as retrospective meta-analyses of clinical trials, have consistently demonstrated that DPP-4 inhibitors are not associated with any increase in cardiovascular adverse events, and have even pointed towards a risk reduction. The combination therapy of Alogliptin with other agents like metformin and pioglitazone have been shown to provide better and superior efficacy as compared to individual monotherapy. The hypoglycemic risk is less with Alogliptin. Alogliptin has been shown to be associated with less risk of hepatotoxicity, weight gain, and acute pancreatitis. Alogliptin does not worsen outcomes in patients with a history of heart failure (HF), neither does it increase rate of new hospitalization for heart failure (HF), as per the data from EXAMINE trial.\",\"PeriodicalId\":13313,\"journal\":{\"name\":\"Indian Journal of Pharmacy and Pharmacology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Pharmacy and Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.ijpp.2023.013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmacy and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijpp.2023.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

DPP-4抑制剂在市场上已经存在了近十多年。在T2DM的治疗中,DPP-4抑制剂是公认的治疗选择。美国fda于2008年发布了新的抗糖尿病药物批准前和批准后以及CV安全性的精确指南。综合安全性分析的中性效应以及临床试验的回顾性荟萃分析一致表明,DPP-4抑制剂与心血管不良事件的任何增加无关,甚至指向风险降低。阿格列汀与其他药物如二甲双胍和吡格列酮联合治疗已被证明比单独治疗提供更好和更优越的疗效。阿格列汀的低血糖风险较低。阿格列汀与肝毒性、体重增加和急性胰腺炎的风险较低有关。根据来自EXAMINE试验的数据,阿格列汀不会恶化有心力衰竭(HF)病史患者的预后,也不会增加心力衰竭(HF)新住院率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Commentary on cardiovascular safety of DPP4Is: Focus on Alogliptin
DPP-4 inhibitors are present in the market for almost more than a decade. In Management of T2DM, DPP-4 inhibitors are established therapy option. The precise guidance for the pre- and post-approval and also CV safety of the newer antidiabetic agents was released by the USFDA in 2008. A neutral effect of Pooled safety analyses, as well as retrospective meta-analyses of clinical trials, have consistently demonstrated that DPP-4 inhibitors are not associated with any increase in cardiovascular adverse events, and have even pointed towards a risk reduction. The combination therapy of Alogliptin with other agents like metformin and pioglitazone have been shown to provide better and superior efficacy as compared to individual monotherapy. The hypoglycemic risk is less with Alogliptin. Alogliptin has been shown to be associated with less risk of hepatotoxicity, weight gain, and acute pancreatitis. Alogliptin does not worsen outcomes in patients with a history of heart failure (HF), neither does it increase rate of new hospitalization for heart failure (HF), as per the data from EXAMINE trial.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信